Anja Sandström
Professor vid Institutionen för läkemedelskemi; Läkemedelsdesign och läkemedelsutveckling
- Telefon:
- 070-167 97 76, 018-471 50 26
- Fax:
- 018-471 44 74
- E-post:
- anja.sandstrom@ilk.uu.se
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postadress:
- Box 574
751 23 UPPSALA
- Akademiska meriter:
- apot. FarmD, Docent i Läkemedelskemi
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
I currently serve as the Deputy Dean of Education at the Faculty of Pharmacy. Additionally, I have been recognized as an excellent teacher and hold the position as professor in Medicinal Chemistry. My research interests primarily focus on peptides and peptidomimetics in drug discovery.
Biografi
Denna text finns inte på svenska, därför visas den engelska versionen.
I earned a Master's degree in Pharmacy in 1997 and completed my PhD in medicinal chemistry in 2003, studying under Professor Anders Hallberg at Uppsala University. I started my career at the same university as a research scientist. I became an associate professor (docent) in 2009 and a university lecturer in 2011. In 2013, I spent time as a STINT fellow at Amherst College in Massachusetts, USA. Over the years, I've received several teaching awards from Uppsala University and the Pharmaceutical Student Union. In 2017, I was recognized as an excellent teacher, and in 2021, I was promoted to the position of Professor. I've also taken on various leadership roles, including Study Director and Deputy and Assistant Head of the Department of Medicinal chemistry. Currently, I serve as the Deputy Dean of Education at the Faculty of Pharmacy. My research primarily focuses on peptides and peptidomimetics in drug discovery, with a special interest in developing pharmaceutical compounds for infectious diseases.
Publikationer
Senaste publikationer
- Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses (2022)
- Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors (2021)
- Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors (2021)
- The amino-terminal heptapeptide of the algesic substance P provides analgesic effect in relieving chronic neuropathic pain (2021)
- Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease (2020)
Alla publikationer
Artiklar
- Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses (2022)
- Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors (2021)
- Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors (2021)
- The amino-terminal heptapeptide of the algesic substance P provides analgesic effect in relieving chronic neuropathic pain (2021)
- Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease (2020)
- Macrocyclic Peptidomimetics as Inhibitors of Insulin-Regulated Aminopeptidase (IRAP) (2020)
- Solid Phase Synthesis of Sulfonimidamide Pseudopeptides and Library Generation (2020)
- Synthesis of Sulfonimidamide-Based Amino Acid Building Blocks with Orthogonal Protecting Groups (2019)
- Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold (2018)
- From the Anti-Nociceptive Substance P Metabolite Substance P (1-7) to Small Peptidomimetics (2018)
- An imidazole based H-Phe-Phe-NH2 peptidomimetic with anti-allodynic effect in spared nerve injury mice (2018)
- Palladium-Catalyzed Aminocarbonylation in Solid-Phase Peptide Synthesis (2017)
- Impact of N-methylation of the substance P 1-7 amide on anti-allodynic effect in mice after peripheral administration (2017)
- Importance of N-and C-terminal residues of substance P 1-7 for alleviating allodynia in mice after peripheral administration (2017)
- Discovery of pyrazinone based compounds that potently inhibit the drug resistant enzyme variant R155K of the hepatitis C virus NS3 protease (2016)
- Efficient and Selective Palladium-Catalysed C-3 Urea Couplings to 3,5-Dichloro-2(1H)-pyrazinones (2015)
- Palladium-Catalyzed Carbonylation of Aryl Iodides with Sulfinamides (2015)
- Preclinical Characterization of Acyl Sulfonimidamides (2015)
- Small constrained SP1-7 analogues bind to a unique site and promote anti-allodynic effects following systemic injection in mice (2015)
- Synthesis of Vinyl- and Aryl–Acyl Sulfonimidamides Through Pd-Catalyzed Carbonylation Using Mo(CO)6 as ex situ CO Source (2015)
- N-terminal truncations of substance P1-7 amide affect its action on spinal cord injury-induced mechanical allodynia in rats (2014)
- Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues (2014)
- Achiral Pyrazinone-Based Inhibitors of the Hepatitis C Virus NS3 Protease and Drug-Resistant Variants with Elongated Substituents Directed Toward the S2 Pocket (2014)
- Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles (2014)
- Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region (2014)
- Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor (2013)
- Constrained H-Phe-Phe-NH2 Analogues With High Affinity to the Substance P 1-7 Binding Site and With Improved Metabolic Stability and Cell Permeability (2013)
- Aminocarbonylation of 4-Iodo-1H-imidazoles with an Amino Acid Amide Nucleophile (2013)
- Synthesis of functionalized furopyrazines as restricted dipeptidomimetics (2012)
- P2-P1 ' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis (2011)
- The effect of substance P1-7 amide on nociceptive threshold in diabetic mice (2011)
- The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system (2011)
- Discovery of Dipeptides with High Affinity to the Specific Binding Site for Substance P1-7 (2010)
- Hepatitis C protease inhibitors based on 2(1H)-pyrazinones (2010)
- Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents (2010)
- Discovery of Achiral Inhibitors of the Hepatitis C Virus NS3 Protease based on 2(1H)-pyrazinones (2010)
- Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V (2010)
- Hepatitis C virus NS3 protease inhibitors (2009)
- A straightforward microwave method for rapid synthesis of N-1, C-6 functionalized 3,5-dichloro-2(1H)-pyrazinones (2009)
- The C-terminal amidated analogue of the Substance P (SP) fragment SP (1-7) attenuates the expression of naloxone- precipitated withdrawal in morphine dependent rats (2009)
- Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality (2008)
- β-Amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors (2008)
- Hepatitis C Virus NS3 Protease Inhibitors Comprising a Novel Aromatic P1 Moiety (2008)
- New developments in the discovery of agents to treat hepatitis C (2008)
- Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3 (2007)
- Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3 (2007)
- Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3 (2007)
- Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors (2007)
- Phenylglycine as a Novel P2 Scaffold in Hepatitis C Virus NS3 Protease Inhibitors (2007)
- Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3 (2006)
- Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors (2004)
- Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase) (2003)
- Vinyl sulfide cyclized analogues of angiotensin II with high affinity and full agonist activity at the AT(1) receptor (2002)
- Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase) (2002)
- Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain (2001)
- An Improved Procedure for N- to C-Directed (Inverse) Solid-Phase Peptide Synthesis (2000)
- Identification of unique and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries
- Design, synthesis, and in vitro biological evaluation of meta-sulfonamidobenzamide-based antibacterial LpxH inhibitors
- Novel peptidomimetic HCV NS3 protease inhibitors spanning the P2-P1´ region
Böcker
Kapitel
Konferenser
